Now here’s a number that will get people’s attention: Prescription drug prices in the United States just recorded their sharpest year-over-year decline in more than six decades.
Not six years. Not sixteen.
More than sixty.
According to the Bureau of Labor Statistics’ latest Consumer Price Index report, prescription drug prices dropped 0.8 percent in July and were down 3.1 percent compared with the same month last year.
The Trump White House is understandably pointing to that statistic and taking a victory lap, saying President Donald Trump is “delivering real relief to American families and putting patients first.”
But here’s the thing: Drug pricing in America is an extraordinarily complicated machine. There are manufacturers, insurers, pharmacies, government programs, generic competitors and those mysterious creatures known as pharmacy benefit managers, or PBMs, sitting in the middle of it all.
So what actually caused prices to fall?
Fred McGrath, president of the Institute for Legislative Analysis, told the Daily Caller News Foundation that generic and biosimilar competition deserves considerable credit.
“Arguably, the largest driver is generic competition,” McGrath said. “Over the last year, several brand drugs representing tens of billions in annual revenue have seen significant price drops from biosimilar competition.”
That’s the old-fashioned power of competition at work: Give buyers more alternatives, and expensive products suddenly have a lot less room to command premium prices.
But McGrath also pointed directly to policy changes under Trump.
“From a policy perspective, the Pharmacy Benefit Manager (PBM) reform package President Trump signed earlier this year has likely had the biggest impact,” he said.
Trump signed the Consolidated Appropriations Act in February, including provisions aimed at reforming PBMs.
Louisiana Republican Sen. Bill Cassidy summed up the complaint about the industry when the legislation became law.
PBM programs “should be about lowering the cost for patients, not about increasing profit for shareholders,” Cassidy said.
Geoffrey Joyce, director of health policy at the University of Southern California’s Schaeffer Center for Health Policy and Economics, also pointed toward the increased attention being paid to these middlemen.
“Spotlight on PBMs and proposed PBM reforms has led to a reduction in business as normal in the [prescription drug] supply chain,” Joyce told the DCNF.
He also cited “increased transparency into the inefficiencies of the Rx drug market” as another possible contributor.
And then there’s TrumpRx.
The administration announced in May that its direct-to-consumer platform would expand to include more than 600 generic medications. Trump had already issued an executive order in May 2025 pursuing “most-favored-nation” pricing intended to give Americans access to prices comparable to those available in other developed countries.
Brownstone Institute President Jeffrey Tucker sees increased retail competition as part of the explanation.
“In my own view, this is due to growing competition in the retail sector, partly due to TrumpRx, but there are many other entries to this as well,” Tucker said.
“It’s increased price competition as new distribution methods replace more cartelized systems of the past.”
So, case closed? Prices are plunging and everybody can stop worrying about prescriptions?
Not exactly.
McGrath cautioned that Americans shouldn’t expect decreases of this magnitude to continue indefinitely.
“Large decreases or increases are unlikely this year,” he said.
He also questioned how much of the current decline can be attributed to most-favored-nation pricing, noting that MFN medications represent fewer than 10 percent of the 841 drugs listed on TrumpRx. McGrath warned that a broader expansion of price controls could eventually produce shortages and discourage the development of new drugs that might otherwise create competition.
There are other complications, too.
NPR reported in January that 16 pharmaceutical companies that had reached agreements with the Trump administration still raised prices on some medications for 2026.
In other words, the overall index can move down while individual patients still encounter medications that cost more.
Prescription drug prices are now at their LOWEST LEVELS in more than 60 years — because of @POTUS and Republicans working to bring down costs for all Americans.
This is what delivering real, positive results for the American people looks like. https://t.co/iX30GJPDg8
— Speaker Mike Johnson (@SpeakerJohnson) August 16, 2026
House Speaker Mike Johnson nevertheless seized on the latest numbers, writing on X that “prescription drug prices are now at their LOWEST LEVELS in more than 60 years — because of @POTUS and Republicans working to bring down costs for all Americans.”
Affordability remains a serious concern heading toward November’s midterm elections.
